Giant Coronary Aneurysms in Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection

• Type of Material: Article
• Authors: D. Sofia Villacis-Nunez, Emory University; Sassan Hashemi, Children's Healthcare of Atlanta; Meghan C. Nelson, Emory University; Elaine Flanagan, Emory University; Amit Thakral, Emory University; Fred Rodriguez III, Emory University; Preeti Jaggi, Emory University; Matthew Oster, Emory University; Sampath Prahalad, Emory University; Kelly Rouster Stevens, Emory University
• Language: English
• Date: 2021-10-06
• Publisher: Elsevier
• Publication Version: Final Published Version
• Copyright Statement: © 2021 The Authors
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.jaccas.2021.06.043
• Title of Journal or Parent Work: JACC: Case Reports
• Volume: 3
• Issue: 13
• Start Page: 1499
• End Page: 1508
• Grant/Funding Information: Dr. Prahalad has received partial support from the Marcus Foundation Inc.; and has served on a Macrophage Activation Syndrome Adjudication Committee for Novartis Pharmaceuticals. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
• Keywords: IVIG, intravenous immunoglobulin; COVID-19; RCA, right coronary artery; multisystem inflammatory syndrome in children; IgG, immunoglobulin G; PCR, polymerase chain reaction; SARS-CoV-2; KD, Kawasaki disease; LAD, left anterior descending; IVMP, intravenous methylprednisolone; SARS-CoV-2, severe acute respiratory distress syndrome-coronavirus-2; MIS-C, multisystem inflammatory syndrome in children; giant coronary aneurysms
• Research Categories: Biology, Virology; Health Sciences, Medicine and Surgery

Abstract

Multisystem inflammatory syndrome in children (MIS-C) can cause a myriad of cardiac manifestations, including coronary dilation and aneurysms; giant aneurysms are infrequent. We describe 3patients with giant coronary aneurysms associated with MIS-C, including the youngest case reported to date, treated with intravenous immunoglobulin, corticosteroids, and biologic agents. (Level of Difficulty: Intermediate.)